• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    FDA Panel Votes For Elamipretide In Barth Syndrome

    PR NEWSWIRE

    After agony, FDA adcomm favors Stealth`s ultra-rare disease drug

    FIERCE BIOTECH

    FDA again raises doubts on Stealth`s ultra-rare disease drug ahead

    ENDPTS

    Stealth BioTherapeutics To Present At UBS Ophthalmology Day

    PR NEWSWIRE

    Stealth BioTherapeutics Shares Bevemipretide Data on Macular Degeneration

    PR NEWSWIRE

    Stealth BioTherapeutics To Participate In Ophthalmology Conferences

    PR NEWSWIRE

    FDA Advisory Committee To Review Stealth`s Elamipretide For Barth Syndrome

    PR NEWSWIRE

    Stealth BioTherapeutics Completes Mid-Cycle Review For Elamipretide In Barth

    PR NEWSWIRE

    Stealth Bio: First Patient In Phase 3 Elamipretide For Dry AMD

    PR NEWSWIRE

    Stealth Biotherapeutics` Barth Syndrome NDA Receives Priority Review Designation

    PR NEWSWIRE

    Stealth Bio At Upcoming Ophthalmology Conferences

    PR NEWSWIRE

    Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug

    ENDPTS

    Stealth Announces FDA Acceptance of NDA for Elamipretide for the Barth Syndrome

    PR NEWSWIRE

    Stealth BioTherapeutics Awarded Grant from The Michael J. Fox Foundation

    PR NEWSWIRE

    Stealth Announces Positive Phase 2 Meeting with FDA ragrading Elamipretide

    PR NEWSWIRE

    Stealth BioTherapeutics Enters into Licensing Agreement with Pharmanovia

    PR NEWSWIRE

    Stealth BioTherapeutics Corp Announces Completion of Merger

    PRNEWSWIRE

    Stealth Announces SBT-272 Data Updates and Orphan Drug Designation

    PRNEWSWIRE

    Nested debuts with plan to jumpstart next-gen precision oncology efforts

    ENPTS

    Stealth handed cloaking device as go-private merger advances

    FIERCEBIOTECH

    STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQ

    PRNEWSWIRE

    Mitochondria biotech receives Morningside buyout offer after PhII fail; & more

    ENDPTS

    Stealth BioTherapeutics Announces Receipt of Preliminary Non-Binding Proposal

    PRNEWSWIRE

    Stealth granted FDA meeting to revive elamipretide filing

    FIERCEBIOTECH

    Stealth BioTherapeutics Presents New SBT-272 Data in ALS Disease Model

    PRNEWSWIRE

    Stealth Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide

    PRNEWSWIRE

    Stealth BioTherapeutics Receives ODD for Elamipretide in DMD

    PRNEWSWIRE

    Reverence Emerges from Stealth

    GLOBENEWSWIRE

    Stealth Bio Posts Disappointing Data From Mid-Stage Geographic Atrophy Study

    BENZINGA

    Stealth Bio Receives ODD from FDA for Elamipretide in Friedreich`s Ataxia

    PRNEWSWIRE

    Stealth BioTx Showcases New DMD Non Data at the 2022 MDA

    PRNEWSWIRE

    Stealth Bio to Present at Mitochondria-Targeted Drug Development Summit

    PRNEWSWIRE

    Stealth BioTherapeutics` Completes Phase 2 Geographic Atrophy Clinical Trial

    PRNEWSWIRE

    Stealth BioTherapeutics Announces Oral Presentation of New DMD Data

    PRNEWSWIRE

    Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs

    PRNEWSWIRE

    Stealth rare disease drug denied by FDA in I told you so moment

    MARKETWATCH

    Stealth BioTherapeutics Receives Refusal to File Letter from the FDA

    PRNEWSWIRE

    Stealth Biotherapeutics soars 8% on preclinical data of potential ALS therapy

    SEEKINGALPHA

    Retrotope misses mark but boosts survival in rare child disorder

    FIERCEBIOTECH

    Stealth Elamipretide NDA Tests Frontiers Of FDA’s Flexibility In Rare Diseases

    PINK SHEET

    Rare disease drugmaker files for approval on adequate trial data; FDA objects

    ENDPTS

    The FDA wants more data. Stealth is filing for approval anyway

    FIERCEPBIOTECH

    Stealth BioTherapeutics Strengthens IP Portfolio with Issuance of Elamipretide

    PRNEWSWIRE

    Stealth BioTherapeutics Joins the Rare Disease Company Coalition

    PR NEWSWIRE

    Stealth BioTherapeutics Announces Poster Presentation at (ACC) Annual Meeting

    PRNEWSWIRE

    Stealth Announces Poster Presentation at American College of Cardiology (ACC)

    PRNEWSWIRE

    Stealth Announces Additional Development Financing to Advance Elamipretide

    PRNEWSWIRE

    Stealth BioTherapeutics Announces Poster Presentation at the 2021 Association

    PRNEWSWIRE

    Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March

    PRNEWSWIRE

    Stealth BioTherapeutics concludes enrolment in Phase II AMD study

    CLINICALTRIALSARENA

    Stealth Completes Enrollment of Ph2 Study Dry Age-Related Macular Degeneration

    PRNEWSWIRE

    Stealth Announces Pricing Of $4.7 Million Registered Direct Offering American

    BIOSPACE

    Stealth BioTherapeutics to Participate in Upcoming January Investor Conferences

    PRNEWSWIRE

    Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide

    PRNEWSWIRE

    Stealth BioTherapeutics Announces Elamipretide Clinical Data

    PRNEWSWIRE

    Stealth Announces Closing of $3.2 Million Registered Direct Offering

    PRNEWSWIRE

    Stealth Bio launches $3.2M registered direct offering

    SEEKING ALPHA

    Stealth BioTherapeutics Announces Development Financing To Advance Elamipretide

    PRNEWSWIRE

    Stealth BioTherapeutics Announces Poster Presentation at(ASHG)

    PRNEWSWIRE

    Stealth BioTherapeutics Announces Poster Presentation

    PRNEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.